| Impact of antiretroviral therapy on the variability of the HCV NS5B polymerase in HIV/HCV co-infected patients. | |
| | |
MedLine Citation:
|
PMID: 21954459 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
ObjectivesAssessment of the impact of antiretroviral drugs on the variability of hepatitis C virus (HCV) NS5B polymerase in HIV/HCV co-infected individuals.MethodsHCV NS5B polymerase was sequenced from plasma at baseline and at the end of follow-up in HIV/HCV co-infected individuals on a stable antiretroviral regimen seen at two outpatient clinics for at least 2 years. The presence of mutations associated with drug resistance to experimental HCV polymerase inhibitors was examined.ResultsSixty-one HIV/HCV co-infected patients (34% HCV-1a, 25% HCV-1b, 18% HCV-3 and 23% HCV-4) were analysed. The mean time on antiretroviral therapy was 52 months. All patients received HIV nucleoside analogues; 66% along with non-nucleoside analogues. The median HCV RNA was 6.1 log at baseline and 6 log IU/mL at the end of follow-up. The median HIV RNA was 4.4 log at baseline and 1.5 log copies/mL at the end of follow-up. No evidence of selection of NS5B polymerase inhibitor resistance mutations was seen when comparing samples collected at baseline and at the end of follow-up from the same individuals. All NS5B sequences from HCV-1a and HCV-3 showed V499A, associated with resistance to HCV non-nucleoside site-1 inhibitors (NNI-1). In addition, HCV-3 showed I482L, associated with resistance to NNI-2, and HCV-4 showed M414L, I482L and V499A, associated with resistance to NNI-3, 2 and 1, respectively. Two HCV-1b patients showed C316N, related with resistance to NNI-4.ConclusionsThe use of antiretroviral drugs does not increase the rate of primary drug resistance mutations to HCV NS5B polymerase inhibitors in HIV/HCV co-infected patients. However, natural polymorphisms associated with reduced susceptibility to some HCV NNIs are common, particularly in HCV variants other than HCV-1b. |
| | |
Authors:
|
Zulema Plaza; Vincent Soriano; Maria Del Mar Gonzalez; Federico A Di Lello; Juan Macias; Pablo Labarga; Juan Antonio Pineda; Eva Poveda |
Related Documents
:
|
21631149 - Persistence and emergence of x4 virus in hiv infection. 20420669 - Maleic anhydride-modified chicken ovalbumin as an effective and inexpensive anti-hiv mi... 15149669 - 5-alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3h)... 15919769 - Stampidine: a selective oculo-genital microbicide. 19355959 - Novel inhibitors of hiv discovered among existing classes of pharmaceutical compounds i... 22204909 - Synthesis and anti-hcv activity evaluation of anilinoquinoline derivatives. 11387809 - Evidence of hypertriglyceridemia in managing hiv patients on efavirenz. 11019449 - Management trends. resting energy expenditure in the haart era. 18087089 - Outbreak of acute viral hepatitis due to hepatitis e virus in hyderabad. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-9-27 |
Journal Detail:
|
Title: The Journal of antimicrobial chemotherapy Volume: - ISSN: 1460-2091 ISO Abbreviation: - Publication Date: 2011 Sep |
Date Detail:
|
Created Date: 2011-9-28 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7513617 Medline TA: J Antimicrob Chemother Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococci.
Next Document: The Basic Helix-Loop-Helix Transcription Factor MYC2 Directly Represses PLETHORA Expression during J...